https://www.selleckchem.com/btk.html This survey may be a potentially reliable and valid instrument to assess risk and protection in different cultures and populations. However, there is still a gap in the instrument's cross-cultural adaptation processes. This survey may be a potentially reliable and valid instrument to assess risk and protection in different cultures and populations. However, there is still a gap in the instrument's cross-cultural adaptation processes. We use massive transfusion in various clinical conditions and it is associated with high mortality. Although some massive transfusion protocols improve patient outcomes, the clinical circumstances requiring it are not well defined. MATRA-A is a multicenter retrospective study. Six University and Training Research Hospitals in Ankara participated in the study. We collected clinical data on patients (>18years) who received massive transfusions (≥10 units/24h) from 2017 through 2019. Overall, 167 (0·27% of transfused patients) received a massive transfusion of 2586 units of red blood cells (1·5% of total RBCs transfused). The median interquartile range values for RBCs, fresh frozen plasma (FFP) and platelets were 13 (11-176), 16 (9-33) and 4 (0-11), respectively. Surgical patients received 90% of massive transfusions. The most common clinical indications for massive transfusion were cardiovascular diseases (42·6%), trauma (20·3%) and malignancies (11%). FFP RBC Platelets ratio was 1·910·5. The overall ato define the areas that need improvement on a national scale. Transfusion reactions (TRs) may cause or contribute to death. Cardiopulmonary TRs are distressing, and collectively account for most transfusion fatalities, though the degree to which they alter survival more broadly is unclear. Deaths (and their timing) after TRs may provide further insights. Adult (tri-hospital network) haemovigilance data (2013-2016) recorded referrals with conclusions ranging from unrelated to transfusion (UTR) to entities